Citius Pharmaceuticals (CTXR) Stock Statistics & Valuation Metrics

Citius Pharmaceuticals has a market cap or net worth of $14.30M. The enterprise value is $16.61M.

Citius Pharmaceuticals has 11,174,466 shares outstanding. The number of shares has decreased by -2.65% in one year.

Citius Pharmaceuticals’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -52.41%.

The current PE Ratio of Citius Pharmaceuticals is ―. Citius Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Citius Pharmaceuticals had revenue of 0.00 and earned -39.43M in profits. Earnings per share was -0.23.

In the last 12 months, operating cash flow was -26.79M and capital expenditures 0.00, giving a free cash flow of -26.79M billion.

Citius Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Citius Pharmaceuticals upcoming earnings date is Feb 6, 2026, Before Open (Confirmed).

Citius Pharmaceuticals as a current ratio of 0.40, with Debt / Equity ratio of 1.54%

In the past 12 months, Citius Pharmaceuticals has paid 576.00K in taxes.

Citius Pharmaceuticals EV to EBITDA ratio is -3.68, with an EV/FCF ratio of -5.04.

Citius Pharmaceuticals has $1.10M in cash and marketable securities with $204.57K in debt, giving a net cash position of -$895.51K billion.

Gross margin is -33.89%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Citius Pharmaceuticals is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy